• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: dbr:Raltegravir     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatEnzymeInhibitors, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAntiretroviralDrugsyago:WikicatAntiviralsyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Agent114778436yago:Antiviral102725367yago:CausalAgent100007347yago:Communication100033020yago:Drug103247620yago:Formula106816935yago:Inhibitor114724436yago:Matter100020827yago:Medicine103740161yago:Message106598915yago:MolecularFormula106817173yago:PhysicalEntity100001930yago:WikicatIntegraseInhibitorsdrugyago:Statement106722453yago:Substance100020090yago:WikicatEnzymeInhibitors New Facet based on Instances of this Class

Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth. Raltegravir was approved for medical use in the United States in 2007. It is on the World Health Organization's List of Essential Medicines. Lamivudine/raltegravir, a combination with lamivudine, is also available.